PSMB5
ENSG00000100804
Target class
Enzyme
Chromosome
14
Approved drugs
3
Clinical candidates (approved and in development)
6
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- Yes
- Other names
- MB1
- Target name
- PSMB5
- Gene name
- Proteasome 20S subunit beta 5
- Gene symbol
- PSMB5
- Protein name
- Proteasome subunit beta type-5 (EC 3.4.25.1) (Macropain epsilon chain) (Multicatalytic endopeptidase complex epsilon chain) (Proteasome chain 6) (Proteasome epsilon chain) (Proteasome subunit MB1) (Proteasome subunit X) (Proteasome subunit beta-5) (beta-5)
- Gene biotype
- Protein coding
- Gene family
- Proteasome
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 196.45
- Tissue specificity (Gini)
- 0.161
- Tissue specificity (tau)
- 0.6
- KEGG gene identifiers
- hsa:5693
- Protein interaction confidence
- 0.948083
- Protein interaction partners
- 60
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 43 more, listed on the interactive page.
- End position
- 23035230
- Start position
- 23016543
- Chromosome
- 14
- Strand
- Reverse
- Cytoplasm . Nucleus . Note=Translocated from the cytoplasm into the nucleus following interaction with AKIRIN2, which bridges the proteasome with the nuclear import receptor IPO9. .
- Centrosome
- Mid piece
- Nucleoplasm
- Principal piece
- PubMed 12181345
- PubMed 34711951
- Tissue specificity (tau)
- 0.600068
- Expression inequality (Gini)
- 0.16112
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 196.45
- Muscle - Skeletal
- 156.54
- Adrenal Gland
- 103.46
- Artery - Aorta
- 103.14
- Uterus
- 103.03
Expression in transcripts per million
- Cells - Cultured fibroblasts196.45
- Muscle - Skeletal156.54
- Adrenal Gland103.46
- Artery - Aorta103.14
- Uterus103.03
- Pituitary101.22
- Artery - Coronary97.76
- Artery - Tibial96.57
- Cervix - Ectocervix95.56
- Fallopian Tube94.8
- Esophagus - Muscularis94.76
- Esophagus - Mucosa94.74
- Nerve - Tibial93.27
- Colon - Sigmoid92.96
- Thyroid91.72
- Cervix - Endocervix90.61
- Esophagus - Gastroesophageal Junction89.57
- Brain - Spinal cord (cervical c-1)89.26
- Bladder88.47
- Cells - EBV-transformed lymphocytes88.46
- Lung87.36
- Brain - Frontal Cortex (BA9)87
- Vagina86.65
- Adipose - Visceral (Omentum)85.5
- Testis85.49
And 29 more, listed on the interactive page.
- GO:0006508
- GO:0006979
- GO:0010498
- GO:0010499
- GO:0043161
- GO:0043248
- GO:0061136
- GO:0000502
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0005839
- GO:0070062
- GO:0004175
- GO:0004298
- GO:0005515
- GO:0008233
Related records
Trials (799)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (6)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Marizomib 20S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor